Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776847 | 0.89 | ESRRG (0.33) | ESR1KDM2BMEN1KMT2A | |
| SCHEMBL4751428 | 0.87 | KIF11 (0.34) | — | |
| SCHEMBL4809484 | 0.86 | ADRB2 (0.33) | — | |
| SCHEMBL4025458 | 0.86 | NPC1 (0.36) | KDM2BMEN1KMT2A | |
| SCHEMBL4024173 | 0.85 | KDM2B (0.33) | KDM2BMEN1KMT2A | |
| SCHEMBL4026418 | 0.84 | KDM1A (0.32) | KDM2B | |
| SCHEMBL4816419 | 0.82 | ESR1 (0.30) | ESR1 | |
| SCHEMBL4778298 | 0.80 | MC4R (0.35) | ESR1 | |
| SCHEMBL4751598 | 0.80 | MET (0.30) | — | |
| SCHEMBL4751728 | 0.79 | MEN1 (0.31) | ESR1KDM2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | ESR1 1025/4885KDM2B 3090/4885GRIN1 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.